What is the clinical evidence from this study?

Study design: Other. Population: Diabetic cardiomyopathy. Intervention: Dusp15 modulation (overexpression or knockout) vs. Wild-type mice. Primary outcome: Cardiac function and remodeling.

What does this research mean for the field?

Dusp15 overexpression protects against systolic and diastolic cardiac dysfunction in diabetic cardiomyopathy by modulating mtHsp70 Thr116 phosphorylation and preserving mito-UPR signaling. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to investigate how Dusp15 regulates the phosphorylation of mtHsp70 and its role in cardiac dysfunction caused by diabetes.

March 9, 2026Open Access

Dusp15 modulates mtHsp70 Thr116 phosphorylation state to preserve mito-UPR and attenuate cardiac dysfunction in diabetic cardiomyopathy

Key Result

Dusp15 overexpression protected against diabetic cardiac dysfunction and remodeling through mtHsp70-associated mitochondrial unfolded protein response signaling.

Key Points

The study aims to investigate how Dusp15 regulates the phosphorylation of mtHsp70 and its role in cardiac dysfunction caused by diabetes.
Analyzed the effect of Dusp15 on mtHsp70 phosphorylation in cardiac cells.
Examined the relationship between Dusp15 and mito-UPR signaling in the context of diabetic cardiomyopathy.
Evaluated cardiac function in a diabetic model to assess the impact of Dusp15 modulation.
Dusp15 positively influences the phosphorylation state of mtHsp70 at Thr116.
Enhanced mtHsp70-associated mito-UPR signaling is observed when Dusp15 is active.
Cardiac dysfunction is attenuated in diabetic cardiomyopathy models with Dusp15 modulation.

Structured PICO

Does Dusp15 modulation or dapagliflozin improve cardiac function and remodeling in mouse models of diabetic cardiomyopathy?

Population

Male C57BL/6J mice with high-fat diet and streptozotocin-induced diabetic cardiomyopathy, evaluated for cardiac function and remodeling over 24 weeks.

Intervention

Dusp15 genetic modulation (overexpression), mtHsp70T116A knock-in, dapagliflozin (40 mg/kg/day via daily intraperitoneal injection), or DCEM1 (60 mg/kg biweekly intraperitoneal injection) for 12 weeks.

Comparator

Wild-type mice, vehicle treatment, or standard chow diet.

Outcome

Cardiac function and remodeling assessed by echocardiography and histological analysis.surrogate

Dusp15 protects against diabetic cardiomyopathy via mtHsp70-associated mitochondrial unfolded protein response and mediates the cardioprotective effects of dapagliflozin.

Limitations

Only male mice were used in the study to minimize experimental variability arising from hormonal fluctuations.

Abstract

Dusp15 is a stress-responsive regulator that protects against diabetic cardiac dysfunction and remodeling through mtHsp70-associated mito-UPR signaling. Targeting the Dusp15-mtHsp70 axis may represent a therapeutic strategy for diabetic cardiomyopathy.

Demander à l'IA

Bookmark

View Full Paper